[go: up one dir, main page]

DK0738390T3 - Surrogater for targetmolekyler og forbedrede referencepaneler - Google Patents

Surrogater for targetmolekyler og forbedrede referencepaneler

Info

Publication number
DK0738390T3
DK0738390T3 DK95906754T DK95906754T DK0738390T3 DK 0738390 T3 DK0738390 T3 DK 0738390T3 DK 95906754 T DK95906754 T DK 95906754T DK 95906754 T DK95906754 T DK 95906754T DK 0738390 T3 DK0738390 T3 DK 0738390T3
Authority
DK
Denmark
Prior art keywords
reactivity
panels
receptor
panel
members
Prior art date
Application number
DK95906754T
Other languages
English (en)
Inventor
Lawrence M Kauvar
Hugo O Villar
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/177,673 external-priority patent/US5587293A/en
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of DK0738390T3 publication Critical patent/DK0738390T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Laminated Bodies (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95906754T 1994-01-06 1995-01-05 Surrogater for targetmolekyler og forbedrede referencepaneler DK0738390T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/177,673 US5587293A (en) 1994-01-06 1994-01-06 Method to identify binding partners
US08/308,813 US5798275A (en) 1994-01-06 1994-09-19 Profiling reference panel enriched by non-IG proteins
PCT/US1995/000081 WO1995018969A1 (en) 1994-01-06 1995-01-05 Surrogates for targets and improved reference panels

Publications (1)

Publication Number Publication Date
DK0738390T3 true DK0738390T3 (da) 2003-07-21

Family

ID=26873529

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95906754T DK0738390T3 (da) 1994-01-06 1995-01-05 Surrogater for targetmolekyler og forbedrede referencepaneler
DK02009879T DK1235072T3 (da) 1994-01-06 1995-01-05 Surrogater for målmolekyler og forbedrede referencefelter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02009879T DK1235072T3 (da) 1994-01-06 1995-01-05 Surrogater for målmolekyler og forbedrede referencefelter

Country Status (11)

Country Link
US (1) US5741653A (da)
EP (1) EP0738390B1 (da)
JP (1) JPH09507300A (da)
AT (2) ATE359509T1 (da)
AU (1) AU700497B2 (da)
CA (1) CA2178096C (da)
DE (2) DE69530179T2 (da)
DK (2) DK0738390T3 (da)
ES (2) ES2284743T3 (da)
PT (1) PT738390E (da)
WO (1) WO1995018969A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4767371B2 (ja) 1996-01-17 2011-09-07 インペリアル・イノベイションズ・リミテッド 細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
AU5902098A (en) * 1997-01-03 1998-07-31 Terrapin Technologies, Inc. Method to classify gene products
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2309345C (en) 1997-11-12 2007-01-23 3-Dimensional Pharmaceuticals, Inc. High throughput method for functionally classifying proteins identified using a genomics approach
CA2314422A1 (en) * 1997-12-18 1999-06-24 Sepracor Inc. Methods for the simultaneous identification of novel biological targets and lead structures for drug development
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
CA2339581A1 (en) * 1998-08-05 2000-02-17 University Of Pittsburgh Modelling organic compound reactivity in cytochrome p450 mediated reactions
US6625547B1 (en) 1998-08-05 2003-09-23 Washington State University Research Foundation Relative rates of cytochrome p450 metabolism
US20040224338A1 (en) * 1998-08-12 2004-11-11 Zycos Inc., A Delaware Corporation Profiling and cataloging expressed protein tags
CA2339817A1 (en) * 1998-08-12 2000-02-24 Zycos Inc. Profiling and cataloging expressed protein tags
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
EP3712897A1 (en) * 2019-03-22 2020-09-23 Tata Consultancy Services Limited Automated prediction of biological response of chemical compounds based on chemical information

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
WO1989003430A1 (en) * 1987-10-13 1989-04-20 Terrapin Diagnostics, Ltd. Method to produce immunodiagnostic reagents
US5217869A (en) * 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5338659A (en) * 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
US5300425A (en) * 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US4963263A (en) * 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5340474A (en) * 1988-03-24 1994-08-23 Terrapin Technologies, Inc. Panels of analyte-binding ligands
EP0557276A1 (en) * 1989-12-29 1993-09-01 University Technologies International Inc. (Uti) Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
FI932080A7 (fi) * 1990-11-09 1993-05-07 Verigen Inc Menetelmä vasta-aineiden havaitsemiseen tarkoitetun analyysijärjestelm än herkkyyden ja/tai spesifisyyden määrittämiseksi

Also Published As

Publication number Publication date
AU700497B2 (en) 1999-01-07
CA2178096C (en) 2004-03-09
DK1235072T3 (da) 2007-07-16
EP0738390B1 (en) 2003-04-02
PT738390E (pt) 2003-07-31
ATE359509T1 (de) 2007-05-15
DE69530179D1 (de) 2003-05-08
JPH09507300A (ja) 1997-07-22
ATE236401T1 (de) 2003-04-15
AU1522195A (en) 1995-08-01
EP0738390A1 (en) 1996-10-23
ES2284743T3 (es) 2007-11-16
DE69535463T2 (de) 2008-01-03
US5741653A (en) 1998-04-21
DE69535463D1 (de) 2007-05-24
WO1995018969A1 (en) 1995-07-13
ES2196056T3 (es) 2003-12-16
DE69530179T2 (de) 2004-04-08
CA2178096A1 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
DK0738390T3 (da) Surrogater for targetmolekyler og forbedrede referencepaneler
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
BRPI0308585B8 (pt) anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
BR9508417A (pt) Acido nucléico isolado cdna isolado proteina isolada vetor de expressão processo para detectar câncer e pré-câncer de pulmão processo para selecionar especimes humanas para proteina hcaviii processo para testar amostra de célula humana anticorpo e composição terapêutica
ATE297950T1 (de) Testverfahren und reagenzien zur quantifizierung von hbnp
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
DE59814441D1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
DE3486356D1 (de) Von polypeptiden induzierte monoklonale antikörper gegen oncoproteine.
DK159826C (da) Monoklonalt antistof af typen igg1, og fremgangsmaade til fremstilling deraf, fremgangsmaade til bestemmelse af hba1c samt diagnostisk kit til brug derved
Righetti et al. The proteome: anno Domini 2002.
Segura et al. Procedures for monitoring recombinant erythropoietin and analogues in doping control
DK1117685T3 (da) Behandling af inflammatorisk sygdom
CN105277712A (zh) 一种鉴定赖氨酸ε-氨基侧链单甲基化修饰的方法
DK26587A (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
DE69018968D1 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
DK0789844T3 (da) Anvendelse af et BMP-proteinreceptor-kompleks til screening for aktive stoffer i knoglemetabolisme og celler, der er cotransficieret med en type II-BMP-receptor og en type I-BMP-receptor
SE0003566D0 (sv) A method for the quantitative determination of one or more compounds
Gooderham In situ peptide mapping of proteins following polyacrylamide gel electrophoresis
DK162726C (da) Fremgangsmaade til eliminering af falsk positive resultater ved bestemmelse af atl virus-antistof og reagens dertil
ATE427495T1 (de) Diagnoseverfahren fur proteinprofilierung
Lelong et al. Solid immunoassay and immunonephelemetric methods for serum C reactive protein (CRP) determination: discrepancy in CRP value for a patient presenting a monoclonal immunoglobulin G
Chen et al. On-line post-capillary affinity detection of immunoglobulin G for capillary zone electrophoresis
ATE249047T1 (de) Verfahren zum spezifischen nachweis von glykosilierten proteinen